Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
IGF-1 LR3 activates the IGF-1 with similar affinity to native IGF-1 but reduced binding to circulating IGFBPs, increasing its in research models. involves PI3K/Akt and pathways implicated in cellular growth and survival.
02
Research applications
- Cell-culture supplement and bioreactor research
- Animal-physiology and developmental research
- IGF-axis pharmacology
- Recombinant protein expression methodology
Evidence at a glance
What's behind this profile
3 citations · 1999–2023
- Other
- 3
Studies that did not match the categories above.
Publication years
- 99
- 00
- 01
- 02
- 03
- 04
- 05
- 06
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris
2023
Lu Z et al. · Applied Microbiology and Biotechnology
- Model
- Recombinant protein expression in Pichia pastoris (15-L bioreactor)
- Sample
- N/A (bioprocess methodology)
Reported successful high-level expression of IGF-1 and LR3 IGF-1 as xylanase-fusion proteins in P. pastoris with retained bioactivity.
Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers
1999
Hill RA et al. · Domestic Animal Endocrinology
- Model
- In vivo — intravenous infusion in undernourished beef heifers
- Sample
- Not reported in abstract
Long(R3)-IGF-1 infusion in undernourished heifers was associated with a tendency for whole-body and skeletal muscle protein to be conserved.
Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep
2020
Jonker SS et al. · FASEB Journal
- Model
- In vivo — near-term fetal sheep with surgical instrumentation
- Sample
- Fetal sheep at 127–134 days gestation (n not specified in abstract)
IGF-1 LR3 treatment in fetal sheep was associated with increased cardiomyocyte proliferation alongside matched coronary vascular expansion.
Evidence caveats
- IGF-1 LR3 is not approved for human therapeutic use in any jurisdiction. The published literature is dominated by cell-culture, biomanufacturing, and animal-physiology research.
- Like other IGF-axis agents, LR3 IGF-1 is on the World Anti-Doping Agency prohibited list.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain cold-chain and batch traceability for cell-culture and research reagent use.
- Avoid repeated cycles for stock solutions.
- Research-only inventory; not for human use.